DUBLIN--(BUSINESS WIRE)--Aug 24, 2018--The "Myasthenia Gravis - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

'Myasthenia Gravis - Pipeline Insight, 2018' report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Myasthenia Gravis development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Key Topics Covered:

1. Report Introduction

2. Myasthenia Gravis Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Products in Clinical Stage

6. Products in Pre-Clinical and Discovery Stage

7. Therapeutic Assessment

8. Inactive Products

Companies Mentioned

Achillion Pharmaceuticals Inc Alexion Pharmaceuticals Inc Apellis Pharmaceuticals Inc ArGEN-X BV CuraVac Inc GlaxoSmithKline Plc HanAll Biopharma Co Ltd Karus Therapeutics Ltd Millennium Pharmaceuticals Inc Neurotune AG Novartis AG

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/b97bht/myasthenia_gravis?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180824005263/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/24/2018 10:58 AM/DISC: 08/24/2018 10:58 AM

http://www.businesswire.com/news/home/20180824005263/en